Biopharma acquisitions slow, but it's not Covid-19's fault yet
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
Biopharma’s big bet on cancer is laid bare
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
What makes a great year for takeovers?
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
Medtech venture investors wait longer for an exit
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
Deal-depressed third quarter leaves nowhere to hide
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Biopharma set for a big buyout year – on dollar terms at least
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Big device deals are back in fashion
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
